Search

IBM, WellPoint, Inc., and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.

… Friday, February 8, 2013 IBM (NYSE: IBM ), WellPoint, Inc. (NYSE: WLP ), and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to

Researchers at Memorial Sloan Kettering Cancer Center have found that change in PSA levels over time - known as PSA velocity - is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.

… Thursday, February 24, 2011 Screening for PSA Velocity Leads to Many Unnecessary Biopsies and Should Be Removed from Screening Guidelines Researchers at Memorial Sloan Kettering Cancer Center have found that change in PSA levels over time — known as PSA velocity — is a poor predictor of prostate cancer

Carol Morris, MD, MS, has assumed the position of Chief of the Orthopaedic Surgery Service at Memorial Sloan Kettering Cancer Center (MSK).

… Friday, October 14, 2022 Carol Morris, MD, MS, has assumed the position of Chief of the Orthopaedic Surgery Service at Memorial Sloan Kettering Cancer Center (MSK). A skilled surgeon and talented leader, Dr. Morris has a deep familiarity with MSK, having previously spent 14 years at the institution as

Memorial Sloan Kettering researchers helped to identify a key insight into what first goes wrong in the development of many leukemias.

… Thursday, June 30, 2011 Researchers at Memorial Sloan Kettering Cancer Center and New York University have discovered how a mutation in the gene known as TET2 contributes to the development of some leukemias . When a mutation in TET2 occurs, it enhances the function of blood stem cells in the bone marrow

Learn about Jakki Stout’s journey from MSK nurse practitioner to breast cancer patient and back to being an even more helpful and inspiring nurse at MSK.

… Monday, June 10, 2024 It’s easy to see that nurse practitioner Jaclyn Stout has a true passion for nursing. Jakki, as she’s called, is a skilled and compassionate caregiver who’s been at Memorial Sloan Kettering Cancer Center (MSK) for 10 years. She loves her work caring for surgery patients recovering

Risk-reducing salpingo-oophorectomy brings on early menopause and its attendant consequences. Researchers are exploring whether a less drastic surgical strategy can offer a safe and efficacious option.

… Friday, September 16, 2016 Since there is no effective screening test for ovarian cancer , the gold standard management approach for women who are at an increased risk for developing ovarian cancer is a risk-reducing salpingo-oophorectomy (RRSO), a surgical procedure to remove ovaries and fallopian tubes

Many women are confused by conflicting guidelines on breast screening. And the latest recommendations made by the USPSTF are adding to that confusion. MSK experts are available to answer questions and explain what MSK recommends and why it is not altering its guidelines. To schedule an interview with a member of MSK’s breast cancer leadership team, please contact Nicole McNamara at [email protected].

… Monday, January 11, 2016 Many women are confused by conflicting guidelines on breast screening. And the latest recommendations made by the USPSTF are adding to that confusion. MSK experts are available to answer questions and explain what MSK recommends and why it is not altering its guidelines. To schedule

Women and ethnic minorities are underrepresented in science. Memorial Sloan Kettering is working to change that.

… Friday, November 2, 2018 Edwin Kamau (NYU) and Laura González-Fajardo (University of Connecticut) Graduate students Edwin Kamau (NYU) and Laura González-Fajardo (University of Connecticut) Patrick Cherubin (University of Central Florida) and Michael Riley II (University of Florida) Graduate students

Overcoming resistance to drug treatment for lung cancer is a critical challenge.

… Thursday, November 29, 2018 Summary Investigators are looking for ways to overcome resistance to drugs that target lung cancer. Lung cancer was one of the first cancers that could be targeted by drugs aimed at specific mutations in tumors. Advances in genomic medicine and the molecular analysis of tumors

Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years.

… Wednesday, September 27, 2006 Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years. The 561 prostate